Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
UNIFORM PHARMACY PRIOR AUTHORIZATION REQUEST FORM CONTAINS CONFIDENTIAL PATIENT INFORMATION Complete this form in its entirety and send to Rocky Mountain Health Plans at 858-357-2538 Urgent 1 Non-Urgent Requested Drug Name: Increlex® (mecasermin) SubQ Inj. Patient Information: Prescribing Provider Information: Patient Name: Member/Subscriber Number: Policy/Group Number: Patient Date of Birth (MM/DD/YYYY): Patient Address: Prescriber Name: Prescriber Fax: Prescriber Phone: Prescriber Pager: Prescriber Address: Patient Phone: Patient Email Address: Prescriber Office Contact: Prescriber NPI: Prescriber DEA: Prescriber Tax ID: Specialty/Facility Name (If applicable): Prescriber Email Address: Prescription Date: Prior Authorization Request for Drug Benefit: New Request Reauthorization Patient Diagnosis and ICD Diagnostic Code(s): Drug(s) Requested (with J-Code, if applicable): Strength/Route/Frequency: Unit/Volume of Named Drug(s): Start Date and Length of Therapy: Location of Treatment: (e.g. provider office, facility, home health, etc.) including name, Type 2 NPI (if applicable), address and tax ID: Clinical Criteria for Approval, Including other Pertinent Information to Support the Request, other Medications Tried, Their Name(s), Duration, and Patient Response: Increlex® (mecasermin) SubQ Inj. Diagnosis (documentation of diagnosis and lab results supportive of growth failure required) Child with severe, primary insulin-like growth factor deficiency (Primary IGFD) Child with growth hormone gene deletion who has developed neutralizing antibodies to growth hormone Other (please state): ________________________________________________________________________________ Clinical Consideration (for approval, please indicate and provide documentation of the following): Child (age ≥ 2 years old) meets the definition of severe Primary IGFD if: Height standard deviation score ≤ -3.0 AND Basal IFG-1 standard deviation score ≤ -3.0 AND Normal or elevated growth hormone (GH) Updated 12/8/15 Physician Specialty Physician experienced in the diagnosis and management of patients with growth disorders Other: ______________________________________________________________________________________________ For use in clinical trial? (If yes, provide trial name and registration number): Drug Name (Brand Name and Scientific Name)/Strength: Dose: Quantity: Route: Number of Refills: Product will be delivered to: Patient’s Home Frequency: Physician Office Other: Date: Prescriber or Authorized Signature: Dispensing Pharmacy Name and Phone Number: Approved Denied If denied, provide reason for denial, and include other potential alternative medications, if applicable, that are found in the formulary of the carrier: 1. A request for prior authorization that if determined in the time allowed for non-urgent requests could seriously jeopardize the life or health of the covered person or the ability of the covered person to regain maximum function, or subject the person to severe pain that cannot be adequately managed without the drug benefit contained in the prior authorization request RMHP Formulary Coverage Policy THIS INFORMATION IS NOT ALL-INCLUSIVE AND IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY Increlex® (mecasermin [rDNA origin] injection) CLASSIFICATION Endocrine Metabolic Agent DESCRIPTION Mecasermin is a recombinant form of human insulin-like growth factor I (rhIGF-I) that mediates anabolic and growth-promoting effects of growth hormone. Endogenous Insulin Growth Factor1 (IGF-1) is required for normal growth and brain development. IGF-1 is in part directed towards stimulating the uptake of glucose, fatty acids, and amino acids so that metabolism supports growing tissues. Endogenous IGF-1 increases in insulin sensitivity; mimics some actions of insulin (has a 6 to 11% of glucose-lowering effect) and therefore has hypoglycemic potential. Indicated for the long-term treatment of children with severe primary insulin-like growth factor deficiency (Primary IGFD) or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone Severe Primary IGFD is defined by: height standard deviation score ≤ -3.0 and basal IGF-1 standard deviation score ≤ -3.0 and normal or elevated growth hormone (GH) Severe Primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signaling pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment. Increlex is not a substitute for GH treatment. Increlex is not intended for use in subjects with secondary forms of IGF-1 deficiency, such as GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of antiinflammatory steroids. Five clinical studies (4 open-label and one double-blind, placebo controlled) were conducted in 71 pediatric patients with severe Primary IGFD. The dose of mecasermin ranged from 0.06 to 0.12 mg/kg subcutaneously twice daily. Patient enrollment was based on extreme short stature, slow growth rates, low IGF-1 serum concentrations, and normal growth hormone secretion. The data from all 5 trials was pooled to allow a global efficacy and safety analysis. 61 patients completed at least one year of treatment and 13 patients completed 8 years of treatment. Fifty-three (87%) had Laron Syndrome; 7 (11%) had growth hormone gene deletion; and 1 (2%) had neutralizing antibodies to growth hormone. Pre-treatment height velocity was available for 58 patients and after 1 year of treatment the change from pre-treatment was significant (p< 0.0001). Significant results in height velocity continued through year 6 (p = 0.0009) of treatment and by year 8 the mean (SD) for change from pre-treatment was +0.7 (2.5) resulting in a p-value of 0.3059. The evaluation of bone age advancement was conducted in 49 patients on mecasermin. The mean SD change in chronological age was 4.9 +/- 3.4 years and the change in bone age was 5.3 +/- 3.4 years. Increlex can be self-administered. FORMULARY COVERAGE Prior authorization: Required Good Health Formulary: Tier 5; Age limit restriction of 2 years of age and older Commercial Formulary: Tier 6; Age limit restriction of 2 years of age and older Medicare Part D coverage: Tier 3; Age limit restriction of 2 years of age and older (effective 1/1/2015) COVERAGE CRITERIA Increlex® (mecasermin) meets the definition of medical necessity for the following: Long-term treatment of children with severe primary insulin-like growth factor deficiency (Primary IGFD) or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone. o Documentation required supportive of diagnosis, Severe Primary IGFD, as defined as: Height standard deviation score ≤ -3.0 and Basal IGF-1 standard deviation score ≤ -3.0 and Normal or elevated growth hormone (GH) Severe Primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signaling pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, that cannot be expected to respond adequately to exogenous GH treatment. Increlex is not a substitute for GH treatment. Increlex® (mecasermin) is considered experimental for the following: Any condition or diagnosis not FDA approved or Compendia supported including: Secondary forms of IGF-1 deficiency (e.g., GH deficiency, malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids) Amyotrophic lateral sclerosis Adjuct in Diabetes mellitus type 2 Required Provider Specialty: Approval is limited to physicians who are experienced in the diagnosis and management of patients with growth disorders DOSAGE/ADMINISTRATION Pediatric Dosing (safety and efficacy has not been determined for pediatric patients less than 2 years): Primary IGF-1 deficiency (Severe): The dosage of mecasermin should be individualized for each patient. The recommended initial dose is 0.04 to 0.08 mg/kg subQ twice daily. Once mecasermin is well tolerated for at least 1 week, the dose may be increased by 0.04 mg/kg per dose, to a maximum of 0.12 mg/kg subQ twice daily. Patients should monitor their preprandial glucose at the initiation of therapy, if frequent symptoms of hypoglycemia occur and until a well-tolerated dose is established. Mecasermin should always be given shortly before or after (+/- 20 minutes) a meal or snack. If the patient cannot eat a meal or snack before or after administration, the dose of mecasermin should be omitted. Subsequent doses of mecasermin should never be increased to make up for omitted doses. If hypoglycemia occurs despite adequate food intake, the dose of mecasermin should be decreased and careful monitoring of glucose levels should continue. PRECAUTIONS Contraindications: o Allergy or severe hypersensitivity to mecasermin (rhIGF-1) or any component of the formulation o Growth promotion in patients with closed epiphyses o Intravenous administration o Active or suspected neoplasia - discontinue therapy if evidence of malignancy subsequently develops Precautions: o High-risk activities (e.g., driving or operating machinery) due to hypoglycemic effect. Limit activities within 2 to 3 hours after dosing, particularly when therapy is initiated. o Hypersensitivity and allergic reactions, including anaphylaxis, have been reported. o Hypoglycemic effect, especially in small children. Administer shortly before or after a meal or snack. Monitoring is recommended. Mecasermin may require dose adjustmen.t o Intracranial hypertension has occurred. Perform funduscopic examinations at initiation and intermittently during therapy o Lymphoid tissue (e.g., tonsillar and adenoidal) hypertrophy has occurred. Monitoring is recommended. o Neonates: gasping syndrome and neurologic toxicity due to benzyl alcohol preservative can occur. o History of scoliosis: progression may occur with rapid growth due to mecasermin therapy. Monitoring is recommended. o Slipped capital femoral epiphysis may occur with rapid growth due to mecasermin therapy. Evaluate limp or complaints of hip or knee. Billing/Coding information CPT Coding: 96372 Therapeutic, prophylactic or diagnostic injection (specify substance or drug); subcutaneous or intramuscular HCPCS Coding: J 2170 Injection, mecasermin, 1mg COST AWP (July 2014): Increlex 40mg/4ml (4ml): $3,198.12 GUIDELINE UPDATE INFORMATION July 2014 Prior Authorization and Coverage Policy created REFERENCES DRUGDEX®, accessed 07/16/2014.